BriaCell Therapeutics Corp. Announces US$27.2 Million Private Placement
June 03, 2021 09:41 ET
|
BriaCell Therapeutics Corp.
BERKELEY, Calif. and VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the "Company" or “BriaCell”), a clinical-stage...
BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor
June 02, 2021 07:12 ET
|
BriaCell Therapeutics Corp.
12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade I/II tumors(1)Top Responder: 21.4 months survival plus 100%...
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
May 19, 2021 17:15 ET
|
BriaCell Therapeutics Corp
BERKELEY, Calif. and VANCOUVER, British Columbia, May 19, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director
May 11, 2021 06:30 ET
|
BriaCell Therapeutics Corp
BERKELEY, Calif. and VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.com
April 21, 2021 08:00 ET
|
Briacell Therapeutics Corp.
AUSTIN, Texas, April 21, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics...
BriaCell Announces Investor and Media Outreach Programs
April 15, 2021 18:00 ET
|
BriaCell Therapeutics Corp
BERKELEY, Calif. and VANCOUVER, British Columbia, April 15, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million
April 12, 2021 13:45 ET
|
BriaCell Therapeutics Corp
BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
April 12, 2021 06:30 ET
|
BriaCell Therapeutics Corp
Clinical and pathological data presented from the clinical trials of Bria-IMT™ alone and in combination with immune checkpoint inhibitors in advanced breast cancer indicates high responding subset...
BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021
March 30, 2021 06:30 ET
|
BriaCell Therapeutics Corp
Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American...
BriaCell Announces Closing of US$25 Million Public Offering
February 26, 2021 14:24 ET
|
BriaCell Therapeutics Corp
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage...